Anson Funds

InterRent REIT is a growth-oriented real estate investment trust engaged in increasing Unitholder value and creating a growing and sustainable distribution through the acquisition and ownership of multi-residential properties. InterRent's strategy is to expand its portfolio primarily within markets that have exhibited stable market vacancies, sufficient suites available to attain the critical mass necessary to implement an efficient portfolio management structure and, offer opportunities for accretive acquisitions. InterRent's primary objective is to use the proven industry experience of the Trustees, Management and Operational Team to: (i) provide Unitholders with stable and growing cash distributions from investments in a diversified portfolio of multi-residential properties; (ii) enhance the value of the assets and maximize long-term Unit value through the active management of such assets; and (iii) expand the asset base and increase Distributable Income through accretive acquisitions.

NRx Pharmaceuticals is a clinical-stage pharmaceutical company focused on developing innovative therapeutics for central nervous system disorders and life-threatening pulmonary diseases. The company aims to address serious medical conditions that often lack effective treatments. It has commercialized ZYESAMI (Aviptadil), a therapeutic for COVID-related respiratory failure, and is advancing NRX-100/101, which represents the first sequential drug regimen targeting bipolar depression in patients experiencing acute suicidal ideation and behavior. Additionally, NRx Pharmaceuticals has been awarded exclusive worldwide rights by the Government of Israel to develop and market the BriLife COVID vaccine, enhancing its portfolio in the fight against respiratory illnesses.

NRx Pharmaceuticals is a clinical-stage pharmaceutical company focused on developing innovative therapeutics for central nervous system disorders and life-threatening pulmonary diseases. The company aims to address serious medical conditions that often lack effective treatments. It has commercialized ZYESAMI (Aviptadil), a therapeutic for COVID-related respiratory failure, and is advancing NRX-100/101, which represents the first sequential drug regimen targeting bipolar depression in patients experiencing acute suicidal ideation and behavior. Additionally, NRx Pharmaceuticals has been awarded exclusive worldwide rights by the Government of Israel to develop and market the BriLife COVID vaccine, enhancing its portfolio in the fight against respiratory illnesses.

View is a technology company specializing in smart building solutions, particularly through its innovative smart windows. These windows utilize artificial intelligence to automatically adjust to sunlight, enhancing natural light access and providing unobstructed views while also minimizing heat and glare. This technology not only improves the health and overall experience of occupants but also reduces energy consumption and carbon emissions. View's products are integrated into a cloud-connected smart building platform, which includes essential infrastructure for power, networking, and communication. The company has successfully implemented its solutions in over 90 million square feet of various building types, including offices, hospitals, airports, educational institutions, hotels, and multifamily residences.